Most cited papers from Minerva Biotechnologies (United States)
What are the most cited papers from Minerva Biotechnologies (United States)?
The most cited paper from Minerva Biotechnologies (United States) is "MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells" (Shawn P. Fessler, Mark T. Wotkowicz, Sanjeev K. Mahanta et al., 2009), with 96 citations. Next come "MUC1* Mediates the Growth of Human Pluripotent Stem Cells" (78) and "A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells" (75).
Showing 17 of 17 papers. Every paper is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells Shawn P. Fessler, Mark T. Wotkowicz, Sanjeev K. Mahanta et al. · Breast Cancer Research and Treatment | 4 May 2009 | 96 |
| 2 | MUC1* Mediates the Growth of Human Pluripotent Stem Cells Sherry T. Hikita, Kenneth S. Kosik, Dennis Clegg et al. · PLoS ONE | 2 Oct 2008 | 78 |
| 3 | A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells Sanjeev K. Mahanta, Shawn P. Fessler, Jae-Hong Park et al. · PLoS ONE | 29 Apr 2008 | 75 |
| 4 | Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Thomas N. Seyfried, Jeremy Marsh, Laura M. Shelton et al. · Epilepsy Research | Sep 2011 | 69 |
| 5 | Differential Proteome Analysis of Extracellular Vesicles from Breast Cancer Cell Lines by Chaperone Affinity Enrichment Steve Griffiths, Michelle A. Cormier, Aled Clayton et al. · Proteomes | 8 Oct 2017 | 52 |
| 6 | Laminin and Matrix metalloproteinase 11 regulate Fibronectin levels in the zebrafish myotendinous junction Molly H. Jenkins, Sarah S. Alrowaished, Michelle F. Goody et al. · Skeletal Muscle | 14 Apr 2016 | 41 |
| 7 | A Primitive Growth Factor, NME7AB, Is Sufficient to Induce Stable Naïve State Human Pluripotency; Reprogramming in This Novel Growth Factor Confers Superior Differentiation M.G. Carter, Benoit J. Smagghe, Andrew K. Stewart et al. · Stem Cells | 7 Jan 2016 | 28 |
| 8 | MUC1* Ligand, NM23-H1, Is a Novel Growth Factor That Maintains Human Stem Cells in a More Naïve State Benoit J. Smagghe, Andrew K. Stewart, Mark G. Carter et al. · PLoS ONE | 7 Mar 2013 | 26 |
| 9 | A Gold Nanoparticle Platform for Protein–Protein Interactions and Drug Discovery Andrew B. Thompson, Amy K. Calhoun, Benoit J. Smagghe et al. · ACS Applied Materials & Interfaces | 23 Jun 2011 | 24 |
| 10 | Optimization and validation of an enzyme immunoassay for the insect growth regulator fenoxycarb András Székács, Hong T.M Le, Ferenc Szurdoki et al. · Analytica Chimica Acta | 9 Jun 2003 | 22 |
| 11 | The VM Mouse Model of Glioblastoma Multiforme Thomas N. Seyfried, Laura M. Shelton, Leanne C. Huysentruyt · Neuromethods | 2012 | 4 |
| 12 | Effective CAR T-cell targeting of an MUC1 cleavage product Benoit J. Smagghe, Mark G. Carter, Kevin Yi et al. · Journal for ImmunoTherapy of Cancer | May 2025 | 3 |
| 13 | Novel CAR T that targets MUC1* not full-length MUC1 for treatment of solid tumor cancers Cynthia Carol Bamdad, Andrew K. Stewart, Benoit J. Smagghe et al. · Cytotherapy | 27 Apr 2018 | 3 |
| 14 | First-in-human CAR T for solid tumors targets the MUC1 transmembrane cleavage product Cynthia Carol Bamdad, Andrew K. Stewart, Benoit J. Smagghe et al. · Cytotherapy | May 2019 | 2 |
| 15 | The Wnt pathway induces a naïve-like subpopulation in primed stem cells, while NME7AB leads to a homogeneous naïve-like population Kevin Yi, Jac-Leen S. Nash, Mark G. Carter et al. · PLoS ONE | 25 Jun 2025 | 0 |
| 16 | 89 First-in-human CAR T targets cleaved MUC1, the growth factor receptor form Benoit J. Smagghe, Andrew K. Stewart, Pengyu Huang et al. · Regular and Young Investigator Award Abstracts | Nov 2020 | 0 |
| 17 | 1st-in-human CAR T targets MUC1 transmembrane cleavage product Cynthia Carol Bamdad, Andrew K. Stewart, Pengyu Huang et al. · Cytotherapy | May 2020 | 0 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.